Monsanto’s DeKalb brand seed corn sits at the Crop Production Services warehouse in Illinois. Photographer: Daniel Acker/Bloomberg

Aaron Kirchfeld, Andrew Noel in London and Patrick Winters in Zurich The desire to avoid US corporate taxes has now spread to agricultural giants – as(...)

WhatsUpMum: pregnancy app.

The popularity of smartphones and the availability of apps mean there is a whole world of information at your fingertips. That’s particularly useful w(...)

Property: its gains must be seen in the context of its recent fails

Who has the fairest fund of them all? If you’re looking for an investment with an element of risk, a fund is always an option for diversifying (...)

André Borschberg, Co-founder and CEO and Bertrand Piccard, Initiator and Chairman (in the cockpit)  standing beside the cockpit of Solar Impulse 2, the single seater solar airplane with which they will attempt  the first round-the-world solar flight.  Photograph: Jean Revillard/Rezo.ch

A solar-powered aircraft that will attempt to fly round the world next March was revealed in Switzerland this afternoon. It will fly day and ni(...)

Left to right: 2fm ‘Breakfast Republic’ presenters Bernard O’Shea, Keith Walsh and Jennifer Maguire, with Enda Ryan, Berocca brand manager

2fm’s new morning show Breakfast Republic , which begins on Monday, will be sponsored by mul(...)

The market for MS drugs will grow to $20.2 billion a year by 2017, according to a 2011 report by GlobalData, a London- based research company.

Sanofi failed to win US regulatory approval for its multiple sclerosis drug Lemtrada, denting the company’s ambitions of capturing a larger share of t(...)

Neelam Gupta, a breast cancer patient, is examined at an outpatient clinic in New Delhi. The decision of the manufacturer of Herceptin, a costly yet effective treatment for an aggressive form of breast cancer, to surrender its patent in India has raised concern that such moves threaten the global system for finding cures. Photograph: Lynsey Addario/New York Times

Alka Kudesia needs an expensive drug to treat her breast cancer, but refuses to tell her children for fear they will take out loans to buy the medicin(...)

Bayer made a preliminary offer for Algeta  last month of about $2.4bn, but later raised its bid

Norwegian cancer drug maker Algeta says it has agreed to be acquired by the German drug giant Bayer in a deal valued at about $2.9 billion. Bayer mad(...)

Drugmaker Novartis has yet to invite bids. Photograph: Alan Betson

Novartis’s animal-health business is drawing interest from drugmakers including Eli Lilly and Merck as the Swiss pharmaceutical giant prepares to sell(...)

Bayer acquistion of Algeta to cost about  14.8 billion kroner

Bayer is in early talks to acquire Norwegian partner Algeta for about 14.8 billion kroner, a move that would give Germany’s biggest drugmaker full con(...)